Los Angeles-based Abraxis BioScience is expanding its Phoenix manufacturing facility, creating 200 new jobs in the area. "When all is said and done, this will be a $100 million investment," said Dr. Patrick Soon-Shiong, chairman of Abraxis. The company drug, Abraxane, has been approved in the U.S. and 38 other countries for breast cancer; it's currently in Phase III clinical trials for pancreatic, melanoma and lung cancer. Report